Abstract:2052 Background: Diffuse intrinsic pontine glioma (DIPG) harboring H3.3-K27M mutation is a malignant pediatric brain tumor with a >90% mortality rate within two-year of diagnosis. Current therapeutic options for DIPG are limited. Aiming to improve therapeutic outcomes, we herein report the preliminary findings of a phase I trial studying a neoantigen peptide vaccine targeting H3.3-K27M. Methods: ENACTING is an open-label, single center, two-armed phase 1 trial to assess the safety and T cell immunity of a neoantigen peptide vaccine against H3.3-K27M. Patients aged ≥ 5 years old with newly diagnosed DIPG were consented and screened. HLA-A*02+/H3.3-K27M+ patients were enrolled to a two-arm study: Arm A consists of subjects receiving open debulking surgery, and Arm B consists of subjects without surgery eligibilities who received stereotactic biopsy. All patients subsequently received conformal radiotherapy and neoantigen vaccine treatment designed to elicit both CD4+ and CD8+ T cell immune response. Vaccine was administered intramuscularly in combination with polyinosinic-polycytidylic acid-poly-L-Iysine carboxymethylcellulose (Poly-ICLC). The primary objective is to evaluate the safety (AEs graded by CTCAE v4.03) and survival outcomes. Secondary objectives include maximum tolerated dose (MTD) and immunological responses. Results: As of Jan 2023, 11 patients have been treated, with 7 in Arm A and 4 in Arm B. No grade 3-4 treatment-related adverse events have been observed, with fever (81.9%) and injection site pain (54.5%) being the most common AEs. Among 10 efficacy-assessable patients, median progression-free survival (mPFS) and median overall survival (mOS) were 11.4 months (95% CI: 5.8~14.7) and 15.4 months (95% CI: 7.53~not reached), respectively. One-year OS rate was 66.7% (95% CI: 42~100%). One patient was assessed as complete response (CR). T cell responses against neoantigen were detected and H3.3-K27M mutation-specific CD4 + and CD8 + TCR clones were validated. Conclusions: The H3.3-K27M neoantigen vaccine was well tolerated. Initial results from this ongoing study suggest that, compared with other current therapies against DIPG, H3.3-K27M peptide vaccination may provide superior patient survival outcomes. Clinical trial information: NCT04749641 . [Table: see text]

Diffuse Midline Glioma Treated with Epigenetic Agent-Based Immunotherapy

HiTIP-seq Profiles Epigenomic Reprogramming of Patient-Derived Diffuse Midline Glioma Stem Cells to Epigenetic Therapy

Immunosuppressive Microenvironment in H3K27 Mutant Pediatric Diffuse Midline Glioma: Single-Cell and Bioinformatics Insights on CD8A, IL7R, and ICAM1

Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma

Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges

DIPG-51. DIFFUSE MIDLINE GLIOMAS HIJACK MYELOID CELL POPULATIONS TO INITIATE AN ANTI-INFLAMMATORY TUMOR IMMUNE MICROENVIRONMENT

Targeting Diffuse Midline Glioma with a novel anti-CD99 Antibody

Immunotherapy of Intracranial G422 Glioblastoma with Dendritic Cells Pulsed with Tumor Extract or RNA

Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine Glioma

Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient

Combination of loco-regional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

Path-40. Clinical Characterization Of H3K27M-Mutant Gliomas

Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma

A road map for the treatment of pediatric diffuse midline glioma

Extracellular Histones Profiles of Pediatric H3K27-Altered Diffuse Midline Glioma

Exploring MRI Characteristics of Brain Diffuse Midline Gliomas with the H3 K27M Mutation Using Radiomics

A Novel CDK4/6 Inhibitor Combined with Irradiation Demonstrates Potent Anti-Tumor Efficacy in Diffuse Midline Glioma.

Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma

Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis

National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario

H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.